Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

Fig. 4

Cleaved JAM-A levels are increased in the serum of patients with HER2-positive breast cancer resistant to HER2-targeted therapy. (a) Enzyme-linked immunosorbent assays were used to measure levels of cleaved soluble JAM-A (cJAM-A) in the serum of HER2-positive invasive ductal breast cancer patients who responded to trastuzumab therapy (n = 9) and those who developed a disease recurrence while receiving trastuzumab (n = 11). *P <0.05 by unequal variance unpaired one-tailed t test. (b) Patient characteristics

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us